Table 5. OS and RFS after liver resection in patients with HCC and MVI with only PVTT and in those with PVTT and/or HVTT.
| Country/region | n/n | 1-year, % (95% CI) | P | n/n | 3-year, % (95% CI) | P | n/n | 5-year, % (95% CI) | P |
|---|---|---|---|---|---|---|---|---|---|
| OS* | |||||||||
| Global | 30/5,609 | 54.47 (46.12–62.58) | – | 26/5,395 | 23.20 (16.61–31.42) | – | 19/4,574 | 20.29 (14.23–28.08) | – |
| By country/region* | |||||||||
| China | 20/4,241 | 48.77 (39.14–58.49) | <0.0001 | 17/4,058 | 17.40 (11.26–25.93) | <0.0001 | 8/2,773 | 16.13 (8.61–28.16) | <0.0001 |
| Japan | 2/680 | 79.24 (76.02–82.12) | 2/680 | 41.82 (20.97–66.05) | 3/946 | 28.21 (16.64–43.60) | |||
| Korea | 2/74 | 72.43** (61.21–81.39) | 1/43 | 42.00 (28.33–57.02) | 0/0 | – | |||
| Taiwan | 1/247 | 85.00 (79.98–88.93) | 1/247 | 68.00 (61.93–73.52) | 2/323 | 35.59 (11.01–71.15) | |||
| France | 2/71 | 33.44* (23.48–45.13) | 2/71 | 20.32 (12.51–31.25) | 2/71 | 14.52 (8.07–24.74) | |||
| Italy | 1/62 | 53.30 (40.93–65.27) | 1/62 | 30.10 (20.02–42.56) | 1/62 | 20.00 (11.83–31.78) | |||
| Spain | 1/12 | 66.70 (37.62–86.93) | 1/12 | 33.30 (13.07–62.38) | 1/12 | 22.20 (6.81–52.68) | |||
| United States | 0/0 | – | 0/0 | – | 1/165 | 14.00 (9.49–20.17) | |||
| RFS* | |||||||||
| Global | 15/3,519 | 27.70 (21.00–35.57) | – | 13/3,406 | 10.06 (6.62–15.01) | – | 6/2,059 | 4.31 (0.61–24.76) | – |
| By country* | |||||||||
| China | 9/3,104 | 22.81 (15.45–32.33) | 0.002 | 8/3,022 | 6.35 (4.63–8.65) | <0.0001 | 2/1,718 | 0.10* (0.00–31.83) | 0.37 |
| Korea | 2/74 | 31.17 (19.73–45.48) | 1/43 | 16.00 (7.77–30.09) | 0/0 | – | |||
| France | 1/45 | 32.50 (20.51–47.33) | 1/45 | 11.60 (5.01–24.63) | 1/45 | 11.60 (5.01–24.63) | |||
| Italy | 1/62 | 31.70 (21.37–44.21) | 1/62 | 20.80 (12.45–32.66) | 1/62 | 15.60 (8.52–26.85) | |||
| Spain | 1/12 | 58.30 (30.74–81.50) | 1/12 | 43.70 (19.88–70.83) | 1/12 | 21.90 (6.66–52.41) | |||
n/n, studies/patients; *, some studies encompassed multiple regions, so they were included in the global analysis but not in the regional/country analysis; **, all I2>66.0 with P value <0.05, except for values marked. OS, overall survival; RFS, recurrence free survival; HCC, hepatocellular carcinoma; MVI, macrovascular invasion; PVTT, portal vein tumor thrombosis; HVTT, hepatic vein tumor thrombosis.